The Controversial Role of PD-1 and Its Ligands in Gynecological Malignancies

Area of Science:

• Immunology
• Oncology
• Gynecologic Oncology

Background:

• The programmed death-1 (PD-1) receptor and its ligands, PD-L1 and PD-L2, are critical regulators of T-cell activation and immune checkpoints.
• Expression of PD-L1 and PD-L2 occurs in various cancer cells and their microenvironments, but their prognostic significance and precise roles remain under investigation.
• The PD-1/PD-L1/PD-L2 axis is a key target in cancer immunotherapy, particularly with anti-PD-1 and anti-PD-L1 antibodies.

Purpose of the Study:

• To review the role of the PD-1/PD-L1/PD-L2 axis in gynecological cancers.
• To discuss the current status and challenges of PD-1 axis-targeted therapies in these malignancies.
• To propose strategies for enhancing the clinical efficacy of immunotherapy in gynecological cancers.

Main Methods:

• Literature review of studies investigating the PD-1/PD-L1/PD-L2 axis in gynecological cancers.
• Analysis of existing clinical trial data for anti-PD-1 and anti-PD-L1 therapies.
• Discussion of the potential role of PD-L2 in gynecological malignancies.

Main Results:

• PD-1 ligands are present in ovarian, cervical, vulvar, and uterine cancers, with prognostic correlations potentially dependent on distribution.
• Limited data exists on PD-L2 in gynecological cancers, and its role is not well understood.
• Clinical trials with anti-PD-1/PD-L1 antibodies show safety but low response rates, with ongoing trials for PD-L2 therapies.

Conclusions:

• The PD-1/PD-L1/PD-L2 axis is relevant in gynecological cancers, but its prognostic value and therapeutic implications require further elucidation.
• Clarifying the role of PD-L2 is crucial for optimizing immunotherapy strategies in female malignancies.
• Enhancing the clinical efficacy of PD-1 axis-targeting therapies necessitates addressing current limitations and exploring novel approaches.